Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"Leo never mentions a word about Absssi the past 2 years."

Wrong again. From 3 weeks ago:
"Mr. Ehrlich continued, “This result further validates the breadth of the Brilacidin franchise. Our novel defensin-mimetic drug candidate is anchored with mid-and-late-stage trials in three clinical indications—oral mucositis, inflammatory bowel disease, and serious skin infections—and planned extensions into dermatological diseases, such as atopic dermatitis and acne."